Bertis is a pioneering company in the field of proteomics-based precision medicine, specializing in advanced mass spectrometry analysis services. The company serves clients in academia, biotechnology, and pharmaceuticals, offering tailored solutions that meet the specific needs of research and development in these sectors. Operating primarily in the Asian market, Bertis leverages its proprietary technologies to provide high-quality omics analysis, which includes the renewed Pan-omics Analysis Service Solution (PASS). This service is optimized for detailed and accurate analysis, requiring a minimum sample quantity and specific conditions to ensure precise results. Bertis generates revenue through its specialized services, which are essential for cutting-edge research in early cancer diagnostics and other medical innovations. The company’s business model focuses on providing high-value, technology-driven solutions that address critical challenges in medical research and diagnostics.

Keywords: proteomics, precision medicine, mass spectrometry, omics analysis, biotechnology, pharmaceuticals, cancer diagnostics, R&D, PASS, Asia market.